DE60331827D1 - Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren - Google Patents

Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren

Info

Publication number
DE60331827D1
DE60331827D1 DE60331827T DE60331827T DE60331827D1 DE 60331827 D1 DE60331827 D1 DE 60331827D1 DE 60331827 T DE60331827 T DE 60331827T DE 60331827 T DE60331827 T DE 60331827T DE 60331827 D1 DE60331827 D1 DE 60331827D1
Authority
DE
Germany
Prior art keywords
radioimmun
therapy
compositions
brain tumors
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331827T
Other languages
English (en)
Inventor
Gary L Griffiths
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DE60331827D1 publication Critical patent/DE60331827D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60331827T 2002-05-29 2003-05-28 Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren Expired - Lifetime DE60331827D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38361702P 2002-05-29 2002-05-29
PCT/GB2003/002334 WO2003101495A1 (en) 2002-05-29 2003-05-28 Methods and compositions for radioimmunotherapy of brain and cns tumors

Publications (1)

Publication Number Publication Date
DE60331827D1 true DE60331827D1 (de) 2010-05-06

Family

ID=29711935

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331827T Expired - Lifetime DE60331827D1 (de) 2002-05-29 2003-05-28 Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren

Country Status (8)

Country Link
US (1) US20030235534A1 (de)
EP (1) EP1507562B1 (de)
JP (1) JP2005532343A (de)
AT (1) ATE461713T1 (de)
AU (1) AU2003241024A1 (de)
CA (1) CA2487692A1 (de)
DE (1) DE60331827D1 (de)
WO (1) WO2003101495A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521531B2 (en) * 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US7405320B2 (en) * 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
CA2529027C (en) * 2003-06-13 2013-09-10 Immunomedics, Inc. D-amino acid peptides
US20100068151A1 (en) * 2008-03-11 2010-03-18 Rosenblum Michael G Multimodality molecular imaging with therapeutic conjugates
WO2010144788A2 (en) 2009-06-12 2010-12-16 Cellectar, Inc. Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
SG183272A1 (en) * 2010-02-10 2012-09-27 Fujifilm Ri Pharma Co Ltd Radioactive metal-labeled anti-cadherin antibody
AU2012351743B2 (en) 2011-12-13 2017-07-06 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
CA2985985A1 (en) 2015-05-20 2016-11-24 Kagoshima University Specific modification of antibody by igg-binding peptide
US20200181196A1 (en) * 2016-06-13 2020-06-11 Kagoshima University SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
WO2022167052A1 (en) 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4818706A (en) * 1983-04-19 1989-04-04 American Monitor Corporation Reagent-dispensing system and method
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4900684A (en) * 1987-06-01 1990-02-13 Immunomedics, Inc. CEA immunoassay free of human anti-mouse antibody false positives
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5998222A (en) * 1993-11-29 1999-12-07 Utah State University Reconditioning antibiotic-adulterated milk products
WO1995026206A1 (en) * 1994-03-28 1995-10-05 The Regents Of The University Of California Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU725827B2 (en) * 1996-07-12 2000-10-19 Immunomedics Inc. Radiometal-binding peptide analogues
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69942148D1 (de) * 1998-06-22 2010-04-29 Immunomedics Inc Gebrauch von bispezifischen antikörpern in diagnose und therapie
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67

Also Published As

Publication number Publication date
CA2487692A1 (en) 2003-12-11
EP1507562A1 (de) 2005-02-23
US20030235534A1 (en) 2003-12-25
ATE461713T1 (de) 2010-04-15
JP2005532343A (ja) 2005-10-27
WO2003101495A1 (en) 2003-12-11
AU2003241024A1 (en) 2003-12-19
EP1507562B1 (de) 2010-03-24

Similar Documents

Publication Publication Date Title
RU2342159C2 (ru) Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
UA94899C2 (ru) Фиксированное дозирование антител к her
RU2008150250A (ru) Способ лечения рака
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
EA200500859A1 (ru) Хинолинилпирролопиразолы
HK1071310A1 (en) Combination therapy for the treatment of cancer
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
ATE469220T1 (de) Antikörper, die krebserkrankungen modifizieren
ATE534386T1 (de) Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE413183T1 (de) Verwendung von laminarin in der behandlung von krebs
AU2003244762A1 (en) Methods and compositions for intravesical therapy of bladder cancer
DK1684770T3 (da) Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
ATE348112T1 (de) Krebserkrankungen modifizierende antikörper
TW200724158A (en) Combination therapy in the treatment of cancer
EA200300646A1 (ru) Иммунотерапевтический набор для лечения опухолей
EA202192757A1 (ru) Способ лечения опухолей

Legal Events

Date Code Title Description
8364 No opposition during term of opposition